New psoriasis drug goes Head-to-Head with established treatment
NCT ID NCT05335356
Summary
This study tested a new drug called Bmab 1200 against an already approved drug, Stelara, to see if it works as well for controlling moderate to severe plaque psoriasis. About 384 adults with this skin condition received one of the two drugs for a year, and researchers measured how much their skin cleared up and monitored for side effects. The goal was to see if the new treatment offers a similar level of disease control.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Apex Clinical Research Center
Mayfield Heights, Ohio, 44124, United States
Conditions
Explore the condition pages connected to this study.